BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28057421)

  • 1. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
    Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
    Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
    Vale N; Mäkilä E; Salonen J; Gomes P; Hirvonen J; Santos HA
    Eur J Pharm Biopharm; 2012 Jun; 81(2):314-23. PubMed ID: 22418076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the antituberculosis drug ethionamide.
    Vale N; Gomes P; Santos HA
    Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
    Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
    Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
    Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
    Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
    Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
    Schaaf HS; Victor TC; Venter A; Brittle W; Jordaan AM; Hesseling AC; Marais BJ; van Helden PD; Donald PR
    Int J Tuberc Lung Dis; 2009 Nov; 13(11):1355-9. PubMed ID: 19861006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
    Choi J; Park SJ; Jee JG
    Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis.
    Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM
    mBio; 2019 Apr; 10(2):. PubMed ID: 31015328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
    Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
    Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
    J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.
    Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V
    Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
    Brossier F; Veziris N; Truffot-Pernot C; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 2011 Jan; 55(1):355-60. PubMed ID: 20974869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
    Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
    Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
    Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
    Machado D; Perdigão J; Ramos J; Couto I; Portugal I; Ritter C; Boettger EC; Viveiros M
    J Antimicrob Chemother; 2013 Aug; 68(8):1728-32. PubMed ID: 23539241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity Pattern of Second Line Anti-Tuberculosis Drugs against Clinical Isolates of Multidrug Resistant Mycobacterium tuberculosis.
    Ghafoor T; Ikram A; Abbasi SA; Zaman G; Ayyub M; Palomino JC; Vandamme P; Martin A
    J Coll Physicians Surg Pak; 2015 Apr; 25(4):250-3. PubMed ID: 25899188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
    Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
    Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can inhA mutation predict ethionamide resistance?
    Vadwai V; Ajbani K; Jose M; Vineeth VP; Nikam C; Deshmukh M; Shetty A; Soman R; Rodrigues C
    Int J Tuberc Lung Dis; 2013 Jan; 17(1):129-30. PubMed ID: 23146620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.